{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:17:45Z","timestamp":1792721865399,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.nefroe.2025.501334","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:17:47Z","timestamp":1754579867000},"page":"501334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperuricemia in patients with chronic kidney disease: When and what to treat?"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7614-0830","authenticated-orcid":false,"given":"Marian","family":"Goicoechea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Garc\u00eda-Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.nefroe.2025.501334_bib0005","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1073\/pnas.0904411106","article-title":"Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy","volume":"106","author":"Preitner","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.nefroe.2025.501334_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physiol.00039.2004","article-title":"Molecular physiology of urate transport","volume":"20","author":"Hediger","year":"2005","journal-title":"Physiology"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0015","first-page":"458","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"73","author":"FitzGerald","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2025.501334_bib0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.501334_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med."},{"key":"10.1016\/j.nefroe.2025.501334_bib0030","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501334_bib0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.501334_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0045","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2025.501334_bib0050","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0055","unstructured":"Health Canada. Summary safety review-ULORIC (febuxostat)- assessing a possible risk of drug reaction\/rash with eosinophilia and systemic symptoms (DRESS). http:\/\/www.hcsc.gc.ca\/dhp-mps\/medeff\/reviews-examens\/uloric3-eng.php. (Accessed 4 August 2016)."},{"key":"10.1016\/j.nefroe.2025.501334_bib0060","unstructured":"European Medicines Agency. Adenuric: EPAR product information (last updated: February 5, 2016). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/000777\/WC500021812.pdf."},{"key":"10.1016\/j.nefroe.2025.501334_bib0065","first-page":"251","article-title":"Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?","volume":"48","author":"Paschou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"13","key":"10.1016\/j.nefroe.2025.501334_bib0070","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med."},{"issue":"22","key":"10.1016\/j.nefroe.2025.501334_bib0075","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.nefroe.2025.501334_bib0080","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2025.501334_bib0085","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2025.501334_bib0090","unstructured":"Health Canada. Summary safety review -ULORIC(febuxostat) - assessing the potential risk of heart failure. http:\/\/www.hc-sc.gc.ca\/dhpmps\/medeff\/reviews-examens\/uloric2-eng.php. (Accessed 4 August 2016)."},{"issue":"11","key":"10.1016\/j.nefroe.2025.501334_bib0095","article-title":"Uricosuric medications for chronic gout","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ckj\/sfx036","article-title":"What the nephrologist should know","volume":"10","author":"Sanchez-Ni\u00f1o","year":"2017","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2025.501334_bib0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.nefroe.2025.501334_bib0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.kint.2024.05.033","article-title":"Controversies and practical management of patients with gout and chronic kidney disease","volume":"106","author":"Jonhson","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.501334_bib0120","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.nefroe.2025.501334_bib0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35175-z","article-title":"Effect of fenofibrate on uric acid level in patients with gout","volume":"8","author":"Jung","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2025.501334_bib0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2004.04.005","article-title":"Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia","volume":"148","author":"Milionis","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.nefroe.2025.501334_bib0135","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2025.501334_bib0140","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2025.501334_bib0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kid ney rats","volume":"67","author":"Sanchez-Losada","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0150","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501334_bib0155","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2215\/CJN.04271007","article-title":"Is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes","volume":"3","author":"Rosolowsky","year":"2008","journal-title":"cJASN"},{"key":"10.1016\/j.nefroe.2025.501334_bib0160","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-0227","article-title":"High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes","volume":"33","author":"Ficociello","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nefroe.2025.501334_bib0165","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.2337\/db09-0014","article-title":"Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study","author":"Hovind","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.nefroe.2025.501334_bib0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"Zoppini","year":"2012","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0175","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/TP.0b013e3181c73c18","article-title":"The independent association between serum uric acid and graft outcomes after kidney transplantation","volume":"89","author":"Haririan","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2025.501334_bib0180","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","article-title":"Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal function","volume":"39","author":"Kanbay","year":"2007","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0185","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000105142","article-title":"The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease","volume":"27","author":"Talaat","year":"2007","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501334_bib0195","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1681\/ASN.2010111185","article-title":"Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease","volume":"22","author":"Kao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.501334_bib0200","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effecto of allopurinol in chronic kidney disease (CKD) progressi\u00f3n and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clinical J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.nefroe.2025.501334_bib0205","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2025.501334_bib0210","first-page":"1887","article-title":"A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000331453","article-title":"Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial","volume":"35","author":"Shi","year":"2011","journal-title":"Kidney Blood Press Res."},{"issue":"26","key":"10.1016\/j.nefroe.2025.501334_bib0220","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.nefroe.2025.501334_bib0225","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.501334_bib0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000127837","article-title":"Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia","volume":"108","author":"Sanchez-Losada","year":"2008","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.nefroe.2025.501334_bib0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout. Long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0240","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0245","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2332956","article-title":"Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials","volume":"56","author":"Yang","year":"2024","journal-title":"Ann Med."},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0250","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.kint.2024.10.022","article-title":"Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy","volume":"107","author":"Ghang","year":"2025","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0255","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.kint.2024.11.025","article-title":"Can we crystallize the role of urate-lowering treatment in chronic kidney disease?","volume":"107","author":"Stack","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2025.501334_bib0260","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2188\/jea.10.403","article-title":"Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers","volume":"10","author":"Tomita","year":"2000","journal-title":"J Epidemiol"},{"key":"10.1016\/j.nefroe.2025.501334_bib0265","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor clustering in a screened cohort in Okinawa, Japan","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501334_bib0270","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501334_bib0275","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0280","first-page":"66","article-title":"A preliminary investigation of the association between serum uric acid and impaired renal function","volume":"32","author":"Chen","year":"2009","journal-title":"Chang Gung Med J."},{"key":"10.1016\/j.nefroe.2025.501334_bib0285","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"JASN"},{"issue":"8","key":"10.1016\/j.nefroe.2025.501334_bib0290","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3899\/jrheum.081199","article-title":"Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate","volume":"36","author":"See","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0295","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","article-title":"Uric acid and long-term outcomes in CKD","volume":"53","author":"Madero","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501334_bib0300","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":"Risk factors for end-stage renal disease: 25-year follow up","volume":"168","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.nefroe.2025.501334_bib0305","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1093\/ndt\/gfq262","article-title":"The relationship between serum uric acid and chronic kidney disease among Appalachian adults","volume":"25","author":"Cain","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.501334_bib0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"2","author":"Bellomo","year":"2010","journal-title":"AJKD"},{"key":"10.1016\/j.nefroe.2025.501334_bib0315","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","article-title":"Association of kidney disease with prevalent gout in the United States in 1988\u20131994 and 2007\u20132010","volume":"42","author":"Juraschek","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0320","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/eci.12180","article-title":"Serum uric acid level is associated with the development of microalbuminuria in Korean men","volume":"44","author":"Oh","year":"2014","journal-title":"Eur J Clin Invest."},{"issue":"11","key":"10.1016\/j.nefroe.2025.501334_bib0325","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2215\/CJN.03140315","article-title":"Serum uric acid and risk of CKD in type 2 diabetes","volume":"10","author":"De Cosmo","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0330","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/j.ajkd.2015.06.015","article-title":"Hyperuricemia and progression of CKD in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort study","volume":"66","author":"Rodenbach","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"10.1016\/j.nefroe.2025.501334_bib0335","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10157-019-01705-w","article-title":"Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR & 60 mL\/min\/1.73 m2 and negative proteinuria","volume":"23","author":"Zhou","year":"2019","journal-title":"Clin Exp Nephrol."},{"issue":"8","key":"10.1016\/j.nefroe.2025.501334_bib0340","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.numecd.2020.04.016","article-title":"Uric acid is independent and inversely associated to glomerular filtration rate in young adult Brazilian individuals","volume":"30","author":"Oliveira","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"10.1016\/j.nefroe.2025.501334_bib0345","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2147\/DMSO.S425511","article-title":"Serum uric acid is a better indicator of kidney impairment than serum uric acid-to-creatinine ratio and serum uric acid-to-high-density lipoprotein ratio: a cross-sectional study of type 2 diabetes mellitus patients","volume":"16","author":"Han","year":"2023","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"11","key":"10.1016\/j.nefroe.2025.501334_bib0350","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2169\/internalmedicine.2474-23","article-title":"J-shaped association between serum uric acid levels and the prevalence of a reduced kidney function: a cross-sectional study using japanese health examination data","volume":"63","author":"Kawasoe","year":"2024","journal-title":"Intern Med."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0355","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12872-024-04236-9","article-title":"Kidney function, uric acid, and risk of atrial fibrillation: experience from the AMORIS cohort","volume":"24","author":"Ding","year":"2024","journal-title":"BMC Cardiovasc Disord."},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0360","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/HJH.0000000000000161","article-title":"Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality","volume":"32","author":"Bombelli","year":"2014","journal-title":"J Hypertens."},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0365","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/10641963.2015.1013121","article-title":"Does elevated serum uric acid level predict the hypertension incidence? A Chinese prospective cohort study","volume":"37","author":"Huang","year":"2015","journal-title":"Clin Exp Hypertens."},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0370","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10067-017-3548-2","article-title":"Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort","volume":"36","author":"Cui","year":"2017","journal-title":"Clin Rheumatol."},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0375","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","article-title":"Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study","volume":"69","author":"Kuwabara","year":"2017","journal-title":"Hypertension."},{"issue":"11","key":"10.1016\/j.nefroe.2025.501334_bib0380","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/oby.22000","article-title":"\"Metabolically Healthy\" obesity and hyperuricemia increase risk for hypertension and diabetes: 5-year Japanese cohort study","volume":"25","author":"Kuwabara","year":"2017","journal-title":"Obesity (Silver Spring)."},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0385","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/HYPERTENSIONAHA.118.11390","article-title":"Involvement of arterial stiffness and inflammation in hyperuricemia-related development of hypertension","volume":"72","author":"Tomiyama","year":"2018","journal-title":"Hypertension."},{"issue":"4","key":"10.1016\/j.nefroe.2025.501334_bib0390","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.numecd.2020.12.015","article-title":"Age and sex dependent association of uric acid and incident hypertension","volume":"31","author":"Kim","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"12","key":"10.1016\/j.nefroe.2025.501334_bib0395","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019535","article-title":"Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: the CHIEF study","volume":"99","author":"Lin","year":"2020","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"10.1016\/j.nefroe.2025.501334_bib0400","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.numecd.2021.01.003","article-title":"Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines","volume":"31","author":"Liu","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"8","key":"10.1016\/j.nefroe.2025.501334_bib0405","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.20220241","article-title":"Association between hyperuricemia and hypertension and the mediatory role of obesity: a large cohort study in China","volume":"69","author":"Wang","year":"2023","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0410","doi-asserted-by":"crossref","DOI":"10.1186\/s13690-024-01421-2","article-title":"The role of uric acid in the risk of hypertension developed from prehypertension: a five-year Chinese urban cohort study","volume":"82","author":"Zhu","year":"2024","journal-title":"Arch Public Health."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.nefroe.2025.501334_bib0420","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0425","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1523-1755.2004.00484.x","article-title":"The impact of serum uric acid on cardiovascular outcomes in the LIFE study","volume":"65","author":"H\u00f8ieggen","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.nefroe.2025.501334_bib0430","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.atherosclerosis.2005.09.020","article-title":"Serum uric acid and risk of ischemic stroke: the ARIC Study","volume":"187","author":"Hozawa","year":"2006","journal-title":"Atherosclerosis."},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0435","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","article-title":"Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study","volume":"37","author":"Bos","year":"2006","journal-title":"Stroke."},{"issue":"10","key":"10.1016\/j.nefroe.2025.501334_bib0440","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med."},{"issue":"2","key":"10.1016\/j.nefroe.2025.501334_bib0445","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1373\/clinchem.2007.094425","article-title":"Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men","volume":"54","author":"Strasak","year":"2008","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0450","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/met.2016.0032","article-title":"Association between hyperuricemia and major adverse cardiac events in patients with acute myocardial infarction","volume":"15","author":"Ranjith","year":"2017","journal-title":"Metab Syndr Relat Disord."},{"issue":"6","key":"10.1016\/j.nefroe.2025.501334_bib0455","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/HJH.0000000000000161","article-title":"Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality","volume":"32","author":"Bombelli","year":"2014","journal-title":"J Hypertens."},{"issue":"9","key":"10.1016\/j.nefroe.2025.501334_bib0460","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7180","article-title":"Impact of hyperuricemia and chronic kidney disease on the prevalence and mortality of cardiovascular disease in cancer survivors","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0465","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-024-04055-y","article-title":"Serum uric acid: an independent risk factor for cardiovascular disease in Pakistani Punjabi patients","volume":"24","author":"Hussain","year":"2024","journal-title":"BMC Cardiovasc Disord."},{"issue":"4","key":"10.1016\/j.nefroe.2025.501334_bib0470","doi-asserted-by":"crossref","first-page":"416","DOI":"10.23736\/S0031-0808.21.04357-3","article-title":"The URRAH study","volume":"63","author":"Del Pinto","year":"2021","journal-title":"Panminerva Med."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0475","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12872-016-0379-z","article-title":"Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies","volume":"16","author":"Zuo","year":"2016","journal-title":"BMC Cardiovasc Disord."},{"issue":"11","key":"10.1016\/j.nefroe.2025.501334_bib0480","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/clc.23266","article-title":"The association between hyperuricemia and coronary artery calcification development: a systematic review and meta-analysis","volume":"42","author":"Liang","year":"2019","journal-title":"Clin Cardiol."},{"issue":"2","key":"10.1016\/j.nefroe.2025.501334_bib0485","first-page":"192","article-title":"Mediating effect of hypertension on risk of stroke associated with hyperuricemia","volume":"45","author":"Wang","year":"2024","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0490","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3122\/jabfm.2022.01.210273","article-title":"To treat or not to treat? Effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: a systematic review and network meta- analysis","volume":"35","author":"Tien","year":"2022","journal-title":"J Am Board Fam Med."},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0495","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000522248","article-title":"The effect of allopurinol on renal outcomes in patients with diabetic kidney disease: a systematic review and meta-analysis","volume":"47","author":"Wu","year":"2022","journal-title":"Kidney Blood Press Res."},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0500","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.clinthera.2022.03.014","article-title":"Efficacy of urate-lowering therapy in patients with chronic kidney disease: a network meta-analysis of randomized controlled trials","volume":"44","author":"Yu","year":"2022","journal-title":"Clin Ther."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0505","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12882-024-03491-4","article-title":"Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis","volume":"25","author":"Luo","year":"2024","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0510","article-title":"Effectiveness of urate-lowering therapy for renal function in patients with chronic kidney disease: a meta-analysis of randomized clinical trials","volume":"13","author":"Liang","year":"2022","journal-title":"Front Pharmacol."},{"issue":"2","key":"10.1016\/j.nefroe.2025.501334_bib0515","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/gtmb.2021.0175","article-title":"Genetic association between SLC22A12 variants and susceptibility to hyperuricemia: a meta-analysis","volume":"26","author":"Zheng","year":"2022","journal-title":"Genet Test Mol Biomarkers."},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0520","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10067-021-05956-5","article-title":"Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis","volume":"41","author":"Tsukamoto","year":"2022","journal-title":"Clin Rheumatol."},{"issue":"3","key":"10.1016\/j.nefroe.2025.501334_bib0525","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10067-021-05956-5","article-title":"Prevention of kidney function decline using uricacid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis","volume":"41","author":"Tsukamoto","year":"2022","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.nefroe.2025.501334_bib0530","article-title":"Effectiveness of drug treatments for lowering uric acid on renal function in patients with chronic kidney disease and hyperuricemia: a network meta-analysis of randomized controlled trials","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol."},{"issue":"5","key":"10.1016\/j.nefroe.2025.501334_bib0535","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/imj.14814","article-title":"Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials","volume":"51","author":"Chewcharat","year":"2021","journal-title":"Intern Med J."},{"issue":"29","key":"10.1016\/j.nefroe.2025.501334_bib0540","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016311","article-title":"Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"98","author":"Lin","year":"2019","journal-title":"Medicine (Baltimore)."},{"issue":"13","key":"10.1016\/j.nefroe.2025.501334_bib0545","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010161","article-title":"Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: a PRISMA-compliant article","volume":"97","author":"Zeng","year":"2018","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"10.1016\/j.nefroe.2025.501334_bib0550","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","article-title":"Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"40","author":"Liu","year":"2018","journal-title":"Ren Fail."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T21:08:11Z","timestamp":1757106491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251425000914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2013251425000914"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.501334","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperuricemia in patients with chronic kidney disease: When and what to treat?","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.501334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501334"}}